|  |  |  |  

Clinical Trials
IAS Prevention Guideline plus relevant cardiovascular guidelines from other organizations
Previous and future meetings sponsored by the IAS, the IAS member societies, or relevant affiliated organizations
Current and prior publications that have been sponsored by the IAS, including previous IAS newsletters
Distinguished Fellows of the IAS
Speakers' bureau
Slides available through the IAS, Lorenzini Foundation, and other sites.
IAS monthly newsletter sent by email to all IAS members
Monthly summary of the key literature	in the atherosclerosis field provided each month to all IAS members.
The IAS offers fellowships to young investigators to study in major laboratories
Important websites related to atherosclerosis and related diseases
Computer based algorithms for 10-year risk assessment for cardiovascular disease.
Organizations affiliated with the IAS.


IAS-ISA 2015 Congress
“Translating Atherosclerosis Research into
Novel Therapies for Humans”

(Amsterdam, The Netherlands, May 23-26, 2015)

Scientific Final Program of the Congress

Abstract Book of the Congress


Plenary Sessions

Sunday, May 24, 2015

Monday, May 25, 2015

Plenary Session 4: The HDL Controversy; Is the Particle Irrelevant for Atherogenesis?

HDL Plays No Role in the Pathogenesis of AtherosclerosisNordestgaard, Børge Grønne (Copenhagen, Denmark)

Tuesday, May 26, 2015

Plenary Session 6: Statin Therapy versus Novel Interventions; The Age of Discontent

Statins Are Enough for the Prevention of CVDRay, Kausik (London, UK)

Clinical Breakthroughs Sessions

Sunday, May 24, 2015

Monday, May 25, 2015

Tuesday, May 26, 2015

Clinical Breakthroughs session 3: Modifying LDL cholesterol to prevent CV events

Adverse Events in Patients with LDL-C <25 or <15 mg/dL on ≥2 Consecutive Visits in Fourteen Randomized Trials of AlirocumabRobinson, Jennifer (Iowa City, USA)
Alirocumab treatment effect did not differ between patients with/without low HDL-C or high triglyceride baseline levels in Phase 3 trialsHovingh, Kees (Amsterdam, The Netherlands)
Long-term Treatment with Evolocumab in Patients with Homozygous Familial Hypercholesterolaemia (HoFH): Interim Results from the Trial Assessing Long-Term Use of PCSK9 Inhibition in Subjects with Genetic LDL Disorders (TAUSSIG) StudyRaal, Frederick (Johannesburg, South Africa)
Phase 3 Randomized Trial Evaluating Alirocumab Every Four Weeks Dosing as Add-on to Statin or as Monotherapy: ODYSSEY CHOICE IRoth, Eli (Cincinnati, USA)
Alirocumab in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II studyStroes, Erik (Amsterdam, The Netherlands)